Leica Biosystems to Acquire StatLab Medical Products

Jul 15, 2026
Leica Biosystems has announced an agreement to acquire StatLab Medical Products, expanding its portfolio in anatomic pathology solutions. The deal is expected to close by the end of 2026, pending regulatory approval.

Leica Biosystems has entered into a definitive agreement to acquire StatLab Medical Products, announced in a press release. StatLab is a developer and manufacturer of anatomical pathology products that support laboratories across specimen collection, tissue processing, and slide preparation.

Following the completion of the transaction, StatLab will become part of Leica Biosystems. The acquisition aims to combine StatLab’s product portfolio with Leica Biosystems’ expertise in pathology and diagnostics supported by AI. The companies stated that their combined capabilities will help laboratories improve consistency, standardization, and diagnostic quality.

The deal is expected to close by the end of 2026, subject to customary regulatory approvals. Financial terms of the acquisition were not disclosed.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.